Dr Michael DeRidder | Senior Director, Early Pipeline Commercial Strategy for Oncology Cell Therapy, Neuroscience, and ADD
GSK

Dr Michael DeRidder, Senior Director, Early Pipeline Commercial Strategy for Oncology Cell Therapy, Neuroscience, and ADD, GSK

Dr. DeRidder is a Senior Director in the GSK Early Pipeline Commercial Strategy team, responsible for leading the global Oncology Cell Therapy commercial strategy, with additional responsibility in planning GSK’s overall oncology commercial strategy.  Dr. DeRidder took on this role in early 2016, with the formal creation of the Oncology Cell Therapy Unit within the Oncology Therapy Area.  Prior to this, he led the commercial strategy for various programs and therapy areas within the company, with experience spanning oncology, ophthalmology, neuroscience, hepatology, and a number of other areas.  Dr. DeRidder joined GSK in 2011 following 6 years at LEK Consulting in Boston, where he was an Engagement Manager providing strategic, commercial, and transactional support to a diverse client base within the Life Sciences, covering a wide range of disease areas.  Dr. DeRidder received his Ph.D. in Biomedical Engineering, and recognition as a Towne Fellow, from the University of Pennsylvania and has a BSE from Tulane University in New Orleans.

Appearances:



EAC 2017 Day 2, Wednesday 1st November 2017 @ 09:05

Keynote Panel: Oncology strategies across pharma

  • High level pharma companies come together to discuss their strategies for tackling cancer
  • Each company will give a 5-minute presentation on their strategy, and a fire side discussion on oncology focused strategies will follow
  • Strategies will cover cytotherapy, checkpoint inhibitors, combination therapy, sequential therapy, approaches to solid tumours, treatments and diagnostics
 

back to speakers